Structure Therapeutics Inc ADR
Structure Therapeutics Inc ADR (GPCR) Covered Calls
Structure Therapeutics Inc ADR trades in the Biotechnology industry with an IV Rank of 94.44%, high versus the past year. GPCR's highest covered call setup is the $100.00 strike expiring Jan 15, 2027, sorted by theoretical annualized return. It's 438.50% out of the money with 60 days to expiration, a 438.77% return until expiration, and a 2,669.20% theoretical annualized return. Across the setups shown, annualized returns run from 161.50% to 2,669.20% at strikes between $20.00 and $140.00, with 4 to 431 days to expiration, as of Nov 16, 2026.
Read more
Running GPCR covered calls helps you generate income from Structure Therapeutics Inc ADR shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best GPCR covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call pairs limited risk with a clear income profile. If GPCR stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling GPCR covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given GPCR covered call is worth writing.
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF.
| 2027-01-15 | 60 | 100.00 | 438.50 | 0.05 | 2.15 | 8148.00 | 438.77 | 2669.20 | -0.27 | +0.16 | 18 | 2.10 |
| 2026-11-20 | 4 | 20.00 | 7.70 | 0.20 | 0.70 | 163.00 | 8.78 | 800.96 | -1.08 | +0.31 | 53 | 0.50 |
| 2028-01-21 | 431 | 140.00 | 653.90 | 0.10 | 5.00 | 12153.00 | 654.44 | 554.23 | -0.54 | +0.27 | 68 | 4.90 |
| 2026-12-18 | 32 | 25.00 | 34.63 | 0.50 | 2.65 | 693.00 | 37.32 | 425.66 | -2.69 | +0.34 | 43 | 2.15 |
| 2028-01-21 | 431 | 95.00 | 411.58 | 0.30 | 5.00 | 7673.00 | 413.19 | 349.92 | -1.62 | +0.30 | 7 | 4.70 |
| 2027-04-16 | 151 | 45.00 | 142.33 | 0.30 | 2.85 | 2673.00 | 143.94 | 347.94 | -1.62 | +0.25 | 126 | 2.55 |
| 2028-01-21 | 431 | 75.00 | 303.88 | 1.00 | 5.00 | 5743.00 | 309.26 | 261.90 | -5.39 | +0.33 | 88 | 4.00 |
| 2028-01-21 | 431 | 70.00 | 276.95 | 0.25 | 5.00 | 5168.00 | 278.30 | 235.68 | -1.35 | +0.31 | 37 | 4.75 |
| 2028-01-21 | 431 | 55.00 | 196.18 | 0.85 | 5.00 | 3728.00 | 200.75 | 170.01 | -4.58 | +0.35 | 64 | 4.15 |
| 2027-01-15 | 60 | 22.50 | 21.16 | 1.00 | 4.20 | 493.00 | 26.55 | 161.50 | -5.39 | +0.46 | 260 | 3.20 |
As of Nov 16, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV Rank94.44% High
- Market cap (M$)1,297
- 52 weeks high-80.85%
- 52 weeks low-1.14%
- Analyst recommendationStrong Buy
1.12 - Target price$105.00
494.79% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-09
- P/E—
- Future P/E—
- EPS (ttm)-3.95
- EPS growth next 5 years—
As of Nov 17, 2026